BiBB receives an Intention to Grant for electric-driven EndoDrill in Europe

The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”) announces that the Company has received an Intention to Grant from the European Patent Office (EPO). This means that EPO intends to approve the Company’s first patent application in Europe for EndoDrill®, the world’s first CE-marked electric-driven endoscopic biopsy instrument. A few additional formal steps will follow before a final notice of approval can be issued, after which the granted patent will be valid until October 2039.

BIBB has received an Intention to Grant from the EPO for its patent application EP 19780264.8, which provides a broad protection of the EndoDrill® system, the Company’s latest electric-driven biopsy instrument for advanced endoscopy. In addition to this application, BiBB has three pending international patent applications for EndoDrill®, which have entered the national/regional phase. These applications will be pursued with the intention of providing global IP-protection for the market’s first electric-driven endoscopic biopsy instrument. The Company intends to file additional patent applications with new features and advantages discovered during the continuous development and clinical evaluation of the EndoDrill® system. The EndoDrill® system is currently in clinical phase and the product family will be offered to hospitals working with advanced endoscopy, so-called endoscopic ultrasound (EUS), to improve diagnostics in some of the most serious cancers, such as stomach, pancreas, liver, lung and bladder cancer.

“This advance notice is very positive and important for us as a company and for patients and care providers in Europe! Patent approval in Europe gives us a valuable edge in the commercialization of our EndoDrill® product portfolio. EUS examination is the fastest growing segment within endoscopy, and we see a great interest among physicians for new biopsy instruments that can offer improved sampling of tumors”, says Fredrik Lindblad, CEO of BiBB.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:
Fredrik Lindblad, CEO
Phone: +46 70 899 94 86

This disclosure contains information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 5, 2023.

About BiBBInstruments AB
BiBBInstruments AB is a medical technology company that develops and markets diagnostic instruments under the brand name EndoDrill® for early detection of cancerous tumors. EndoDrill® is the world’s first CE-marked electric-driven endoscopic biopsy instrument. The product is designed to provide larger and more high-quality tissue samples (core biopsies) of suspected tumors than existing products. The product family will include sampling instruments for many of the most serious cancers, such as stomach, pancreas, liver, lung and bladder cancer. EndoDrill® targets the global market for endoscopic biopsy instruments with a focus on the ultrasound-guided biopsy instruments (EUS-FNA/FNB, EBUS-TBNA) segment, which is the fastest growing area in endoscopy. The company was founded in 2013 by Dr Charles Walther, cancer researcher at Lund University and chief physician in clinical pathology at Skåne University Hospital in Lund.

Download press release (PDF)